SCHEMBL24422941

SCHEMBL24422941

O=C(OCc1ccccc1)C1=CCC(C(F)(F)F)OC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.43
KMT2A Q03164 2/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A3 Q01959 1/20 0.43
ALDH1A1 P00352 5/20 0.40
LMNA P02545 2/20 0.40
TSHR P16473 2/20 0.40
MMP2 P08253 2/20 0.39
MMP9 P14780 2/20 0.39
MMP12 P39900 2/20 0.39
MMP1 P03956 1/20 0.39
GPBAR1 Q8TDU6 1/20 0.38
ADORA2B P29275 1/20 0.37
MAPK1 P28482 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
ADORA1 P30542 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20625163 0.73 KMT2A (0.41) TDP1KMT2ASLC6A2SLC6A3ALDH1A1
SCHEMBL20624779 0.73 KMT2A (0.41) TDP1KMT2ASLC6A2SLC6A3ALDH1A1
SCHEMBL16370049 0.70 KMT2A (0.50) TDP1KMT2ASLC6A2SLC6A3ALDH1A1
SCHEMBL22618128 0.70 GABRR1 (0.51) TDP1KMT2ASLC6A2SLC6A3ALDH1A1
SCHEMBL30630598 0.70 TDP1 (0.43) TDP1KMT2ASLC6A2SLC6A3ALDH1A1
SCHEMBL6402746 0.69 TDP1 (0.59) TDP1KMT2ASLC6A2SLC6A3ALDH1A1
SCHEMBL24423839 0.67 ALDH1A1 (0.60) ALDH1A1TSHR
SCHEMBL28266906 0.65 TDP1 (0.54) TDP1KMT2ASLC6A2SLC6A3ALDH1A1
SCHEMBL26813875 0.65 ALDH1A1 (0.47) TDP1KMT2ASLC6A2SLC6A3ALDH1A1
SCHEMBL1991302 0.64 TDP1 (0.53) TDP1KMT2ASLC6A2SLC6A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
CN-116635380-A PPARgamma modulators and methods of use 卫材R&D管理有限公司 2023-08-22 CN disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE PPARG, PPARA, PPARD TDP1 2964/4885KMT2A 4267/4885SLC6A2 4229/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD TDP1 3341/4885KMT2A 2698/4885SLC6A2 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.